Difference between revisions of "Levine RL, et al. Cancer Cell (2005) cited as Ref 316 in DOI: 10.1038/s41392-020-0110-5 (Q9579)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 7, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): Activating mutation in the tyrosine kinase JAK2 in polycythemia vera essential thrombocythemia and myeloid metaplasia with myelofibrosis, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | Activating mutation in the tyrosine kinase JAK2 in polycythemia vera essential thrombocythemia and myeloid metaplasia with myelofibrosis (English) | ||
| Property / title: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera essential thrombocythemia and myeloid metaplasia with myelofibrosis (English) / rank | |||
| + | Normal rank | ||
Revision as of 21:58, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Levine RL, et al. Cancer Cell (2005) cited as Ref 316 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Levine RL
0 references
2005
0 references
Cancer Cell
0 references
7
0 references
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera essential thrombocythemia and myeloid metaplasia with myelofibrosis (English)
0 references
